Amneal Pharma Reports Positive Interim Results From Ongoing Phase 4 ELEVATE-PD Study

December 05, 2025 — 08:39 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study. The company said the first 55 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT extended-release capsules, including significant increases in daily Good On time, reductions in Off time, improved motor symptom control, and consistent gains in Good On time per doseregardless of whether patients switched from immediate-release carbidopa/levodopa, IR CD/LD with a COMT inhibitor, or RYTARY extended-release capsules.

Amneal will present longer-term outcomes and patient-reported results in 2026 as part of the ongoing, rolling ELEVATE-PD program.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Amneal Pharma Reports Positive Interim Results From Ongoing Phase 4 ELEVATE-PD Study

Tags

Latest Articles